ADU S100

Drug Profile

ADU S100

Alternative Names: ADU-S100; MIW 815

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Novartis
  • Class Antineoplastics; Cyclic peptides; Nucleotides; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 20 Dec 2017 Aduro Biotech has patent protection for cyclic dinucleotide structures that activates Stimulator of Interferon Genes pathway in USA
  • 08 Sep 2017 Phase-I clinical trials in Solid tumours and Lymphoma (Combination therapy, Late-stage disease, Metastatic disease) in USA (Intratumoural) (NCT03172936)
  • 09 Aug 2017 Aduro Bitoech and University of California at Berkeley collaborate for development of new immunotherapies before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top